Pharmaceutical News

RSS

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

Ketamine shows rapid antidepressant effects

Researchers have now explored ketamine's effects on suicidality in patients with treatment-resistant depression, and are publishing their results in the September 1st issue of Biological Psychiatry. Ketamine acutely reduced suicidal thoughts when patients were assessed 24 hours after a single infusion. This reduction in suicidality was maintained when patients received repeated doses over the next two weeks.

10 Sep 2009

TI Pharma: A role model of public-private cooperation and partnership

The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.

10 Sep 2009

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Ore Pharmaceuticals Inc., announced today the publication of an article in the online version of the journal Inflammation Research titled, “Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.”

10 Sep 2009

Physicians and patients underestimate promotional volume of Actonel

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patients and physicians most frequently recall Roche's Boniva messages among the ten surveyed osteoporosis brands likely as a result of the Sally Field marketing campaign.

10 Sep 2009

Polio vaccination resumes in Pakistan's Swat Valley

"Authorities in Pakistan's Swat Valley have resumed vaccinating children for polio, an act once banned by Taliban militants, now beaten back by an army offensive," the Associated Press reports. The three-day campaign, which started on Monday, is targeting about 215,000 children, said government official Khurshid Khan.

10 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Biovista's BVA-201 drug for MS shows positive results

Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

10 Sep 2009

Oral GLP-1 Analog approved for human clinical trial

Oramed Pharmaceticals, Inc., a developer of oral drug delivery systems, announced today that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog.

10 Sep 2009

New study highlights the competitive nature of drug development

Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades -- from a median of 10.2 years in the 1970s to 2.5 years in the early part of this decade -- underscoring the competitive nature of drug development, a new study recently completed by the Tufts Center for the Study of Drug Development has found.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

First trial of 2009 H1N1 influenza vaccine testing launched

The first trial testing a candidate 2009 H1N1 influenza vaccine in pregnant women is launching this week, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today.

10 Sep 2009

Clinical study investigates laboratory and clinical implications of proton pump inhibitor drugs

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

ARUP Laboratories' scientist receives grant to research HIV therapies

ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP's Tanya Sandrock, PhD, Research & Development scientist, received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies.

9 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

HCV treatment study reveals low relapse rate of Pegetron

Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.

9 Sep 2009

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF).

9 Sep 2009